Aileron Therapeutics is a clinical stage chemoprotection oncology company dedicated to developing medicines that make chemotherapy safer and more effective, ultimately saving more patients' lives. Their flagship product, ALRN-6924, is a first-in-class MDM2/MDMX dual inhibitor designed to activate p53, which in turn upregulates p21—a known inhibitor of the cell replication cycle. Unlike other chemoprotective agents, ALRN-6924 employs a biomarker strategy and selectively targets p53-mutated cancers in order to protect healthy cells throughout the body while still allowing chemotherapy to kill cancer cells.

By reducing or eliminating chemotherapy-induced side effects, such as dose reductions or delays, Aileron Therapeutics aims to improve patients' quality of life and help them better tolerate chemotherapy. Their mission is to develop a targeted drug that prevents chemotherapy-induced side effects, enabling patients to fight cancer more effectively with a better quality of life. Aileron is committed to bringing chemoprotection to all patients with p53-mutated cancer, regardless of cancer type or chemotherapy regimen